In a mouse model of AD induced by dinitrochlorobenzene (DNCB), AMP-IBP5 administration reduced the levels of IL-4, IL-13, and IL-33, all of which are involved in AD-related inflammation. Here, IL33 is linked to Alzheimer disease.